Ranbaxy lining up new drug delivery system
India's Ranbaxy Laboratories has filed patents in the USA as well asIndia for three novel drug delivery systems for modified products, the Economic Times reports.
The newspaper said Ranbaxy has signed an agreement with Bayer AG to license out to the German firm a delivery system for the anti-infective ciprofloxacin. It quoted the company's executive vice-president and head of research, J M Khanna, as saying that details of the Bayer deal would be unveiled over the next two months, though its value has been estimated by analysts at over $100 million.
Mr Khanna said the new products are in the anti-infective, cardiovascular and antihistamine areas. "In some markets, we will launch on our own and in some others we will go for licensing deals," he added.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze